Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alrizomadlin + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Ascentage Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Alrizomadlin (APG-115) is a novel, orally active small-molecule inhibitor of MDM2 that activates p53-mediated apoptosis in tumor cells and functions as a host immunomodulator. Pembrolizumab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), used as an immune checkpoint inhibitor. The combination of alrizomadlin and pembrolizumab is being investigated for the treatment of advanced solid tumors, including unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), liposarcoma, urothelial carcinoma, malignant peripheral nerve sheath tumor (MPNST), and ATM-mutant solid tumors that have progressed on prior immunotherapy. Alrizomadlin restores TP53 function in wild-type TP53 or MDM2-amplified tumors and may enhance antitumor immunity when combined with PD-1 blockade[1][2][3][4][5].
- Brand names
- Keytruda
- Other names
- alrizomadlin + pembrolizumab
02
Targets
MDM2 (Mouse double minute 2 homolog)TP53 (Cellular Tumor Antigen p53 R175H)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on alrizomadlin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alrizomadlin + pembrolizumab.